BioMarin Pharmaceutical | BMRN - Market Capitalization


BioMarin Pharmaceutical reported $11.12B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
Agios Pharmaceuticals USD 1.61B 598M Nov/2026
Alnylam Pharmaceuticals USD 33.02B 7.17B Sep/2026
Amgen USD 247.94B 20.06B Nov/2026
Bayer EUR 52.42B 5.31B Nov/2026
Biogen USD 33.38B 1.48B Sep/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
Gilead Sciences USD 184.82B 27.96B Sep/2026
Incyte USD 24.6B 1.95B Sep/2026
Insmed USD 24.93B 1.82B Sep/2026
Ionis Pharmaceuticals USD 4.52B 2.9B Nov/2026
Moderna USD 99.14B 22.26B Nov/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Roche Holding CHF 270B 3.66B Jun/2026
Sanofi EUR 114.34B 15.65B Nov/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
United Therapeutics USD 28.64B 5.4B Nov/2026
Vertex Pharmaceuticals USD 140.44B 7.93B Nov/2026